rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Posterior Tibia Nerve Neuroprolotherapy for Dysmenorrhea
Status: Recruiting

The goal of this crossover study is to assessed the treatment efficacy of posterior tibia nerve neuroprolotherapy on dysmenorrhea. The primary outcome is the improvement of Visual Analogue Scale. The main question it aims to answer is:

•Could the posterior tibial nerve neuroprolotherapy alleviate the pain of dysmenorrhea.

Participants will be randomly allocated into two groups, Group-1 will receive neuroprolotherapy in the first 2 menstrual cycles followed by oral acetaminophen(500mg) for the subsequent 2 menstrual cycles. Group02 will received oral acetaminophen(500mg) in initial 2 menstrual cycles, followed by receiving neuroprolotherapy for the subsequent 2 menstrual cycles.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  women aged 18-50 who experience normal menstrual cycles accompanied by menstrual pain  Exclusion Criteria:  Malignant tumors requiring treatment. Pregnant Those who have other acute and chronic pain and are receiving relevant drug treatment. Those who are allergic to acetaminophen or have contraindications. Those who use hormonal contraceptives at the same time. Those with coagulation disorders or taking anticoagulant drugs. - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - GenderDescription: The patients who suffered with dysmenorrhea. - MinimumAge: 18 Years - MaximumAge: 50 Years - StdAgeList: Adult
COronary Microcirculation and Troponin Elevation in Septic Shock
Status: Recruiting

Plasma cardiac troponin (cTn) elevation is an indicator of increased mortality in patients with sepsis yet the underlying cause of troponin elevation in sepsis is not known. The COMTESS study investigates whether elevated high-sensitive cardiac Troponin T (hs-cTnT) levels in hemodynamically unstable patients with sepsis can be explained by an underlying coronary artery disease or a process within the coronary microcirculation. Fifty patients with sepsis and with hs-cTnT elevation (>15 ng/L) will undergo coronary angiography, including an assessment of coronary flow using a method called thermo-dilution to record the index of microcirculatory resistance (IMR) in the left anterior descending artery (LAD). The relationship between IMR and hs-cTnT will subsequently be analysed. It is important to identify the underlying causes of elevated cTn during sepsis to target further research with an aim to improve the survival in patients suffering from this condition.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients fulfilling the Sepsis-3 definition of and diagnostic criteria for sepsis or septic shock Age 40 - 85 years Life expectancy > 1 year hs-cTnT values >15 ng/L  Exclusion Criteria:  pregnancy previous medical history of coronary artery by-pass grafting heart transplant previously verified ejection fraction (EF) ≤39% prior to hospital admission Hypertrophic cardiomyopathy (Septum > 15 mm) severe aortic stenosis amyloidosis or sarcoidosis with myocardial engagement estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 prior to hospital admission asthma infectious endocarditis a medical history of abdominal, thoracic, or orthopaedic surgery within the last three months prior to hospital admission. - HealthyVolunteers: No - Gender: All - MinimumAge: 40 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Sepsis- or septic shock-patients with a life expectancy of >1year and non-normal high-sensitive cardiac troponin T values (>15 ng/L) - SamplingMethod: Non-Probability Sample
The Effect of Progressive Relaxation Exercises on Physiological Parameters, Pain and Anxiety After Cesarean Section
Status: Not yet recruiting

Caesarean section is a surgical procedure that can be performed before or during birth in cases where the life of the mother and fetus is threatened or upon the request of the mother and father. One of the most common problems after cesarean section is abdominal pain. Progressive relaxation exercises are a method that allows certain muscle groups in the body to first contract and then relax. Progressive relaxation exercises have been proven to have positive effects on anxiety. By applying progressive relaxation exercises, the parasympathetic nervous system is activated; Thus, heart and respiratory rate and blood pressure can be kept within normal limits. This study will be conducted to determine the physiological parameters, pain and anxiety levels of progressive relaxation exercises, one of the non-pharmacological methods, on women giving birth by cesarean section.

Eligibility:
- EligibilityCriteria: Inclusion criteria; of postpartum women;  Being between the ages of 20-35, Primiparous pregnancy Having a transverse cesarean section, It should be taken at the 8th hour postoperatively: since mobilization occurs at the 6th hour after the surgery, it should be taken from the 8th hour postoperatively to prevent fatigue in the woman's extremities and to avoid any health problems (nausea-vomiting, headache-waistache) that prevent her from doing the exercises. Primary school graduate, No mental disability or communication problems. Exclusion criteria;  1. Those who have an open wound on their body and/or a diagnosis of allergic disease on their skin, 2. Puerperal complications (bleeding, infection, fever), 3. Those with cardiac arrhythmia and a pacemaker, 4. At risk of experiencing convulsions; Those with diseases such as eclampsia and epilepsy, 5. Those with kidney or liver disease, 6. Those who have practiced progressive relaxation exercises before, 7. Morbidly obese (BKI over 40), 8. Women using chronic opioids, antidepressants, and psychoactive drugs were not included in the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 20 Years - MaximumAge: 35 Years - StdAgeList: Adult
Hybrid Closed Loop Insulin Pump and Bariatric Surgery in Patients With Type 1 Diabetes
Status: Not yet recruiting

Bariatric surgery is increasingly performed on patients with type 1 diabetes. It exposes these patients to an increased risk of hypoglycemia, including severe hypoglycemia, and of severe episodes of hyperglycemia, beyond the perioperative period. The long-term efficacy and safety of hybrid closed-loop insulin pump in these patients has not yet been published.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Major patient With type 1 diabetes for > 1 year Obese (BMI≥30) Having undergone bariatric surgery On a hybrid closed-loop insulin pump Not pregnant No hybrid closed-loop insulin pump discontinuation for more than 45 days after surgery  Exclusion Criteria:  - Patient informed and opposed to data use - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patient with type 1 diabetes who underwent bariatric surgery and treated by hybrid closed-loop insulin pump. - SamplingMethod: Non-Probability Sample
Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases
Status: Not yet recruiting

To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Definite diagnosis of malignant hematologic disease before transplantation, age 12-60 years old, gender is not limited, race is not limited; Patients who are proposed to receive allo-PBSCT for the first time; Eastern Cooperative Oncology Group (ECOG) score 0-2; No serious organ failure and active infection; Voluntary open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; Each subject must sign an informed consent form (ICF) indicating that he/ she understands the purpose and procedures of the study and is willing to participate in the study; in view of the patient's condition, if the patient's own signature is not conducive to the treatment of his/her condition, the ICF will be signed by the legal representative.  Exclusion Criteria:  Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas; Pregnant patients; Patients and/or authorized family members who refuse to undergo an open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at unnecessary risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction; Participants in other clinical studies that may affect aGVHD within 3 months; Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues). - HealthyVolunteers: No - Gender: All - MinimumAge: 12 Years - MaximumAge: 60 Years - StdAgeList: Child, Adult
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
Status: Not yet recruiting

To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT)

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Definite diagnosis of malignant hematologic disease before transplantation, age 12-60 years old, gender is not limited, race is not limited; Patients who are proposed to receive allo-PBSCT for the first time; Eastern Cooperative Oncology Group (ECOG) score 0-2; No serious organ failure and active infection; Voluntary open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; Each subject must sign an informed consent form (ICF) indicating that he/she understands the purpose and procedures of the study and is willing to participate in the study; in view of the patient's condition, if the patient's own signature is not conducive to the treatment of his/her condition, the ICF will be signed by the legal representative.  Exclusion Criteria:  Those with severe organ dysfunction or disease, such as severe disease and dysfunction of the heart, liver, kidneys and pancreas; Pregnant patients; Patients and/or authorized family members who refuse to undergo an open randomized controlled study to observe whether the time of stem cell infusion affects the occurrence of aGVHD after transplantation; Any life-threatening disease, physical condition, or organ system dysfunction that, in the opinion of the investigator, may compromise patient safety and put the results of the study at unnecessary risk; drug-dependent individuals; patients with uncontrolled psychiatric disorders; and individuals with cognitive dysfunction; Participants in other clinical studies that may affect aGVHD within 3 months; Those whom the investigator considers unsuitable for enrollment (e.g., those who anticipate that patients will not be able to adhere to the examination and treatment due to financial and other issues). - HealthyVolunteers: No - Gender: All - MinimumAge: 12 Years - MaximumAge: 60 Years - StdAgeList: Child, Adult
Comparison Between Bupivacaine-Dexmedetomidine Versus Bupivacaine-Dexamethasone in Pericapsular Nerve Group (PENG) Block
Status: Recruiting

The aim of this work is to compare the effectiveness of bupivacaine- dexmedetomidine mixture versus bupivacaine-dexamethasone mixture in PENG Block as Post-operative Analgesia in Hip surgeries

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 18-65 years. Sex: Both sexes. American Society of Anaesthesiologists (ASA) Physical Status Class I and II. Scheduled for hip surgeries under spinal anaesthesia.  Exclusion Criteria:  Declining to give written informed consent. History of allergy to the medications used in the study. Contraindications to regional anesthesia (including patient refusal, coagulopathy and local infection). Psychiatric disorder. American Society of Anesthesiologists (ASA) Physical Status Class III and IV. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
AGMT Austrian Lymphoma Registry
Status: Recruiting

Lymphomas are a group of cancers that originate in the lymphatic system, a key component of the immune system. They can be broadly categorized into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

There are different subtypes of HL, including classical Hodgkin lymphoma (cHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The subtypes of cHL include nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted.

Non-Hodgkin lymphomas are more diverse and comprise a wide range of subtypes, each with distinct genetic, molecular, and clinical features. Common subtypes of NHL include Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), Chronic lymphocytic leukemia (CLL), myeloma, and other rarer subgroups.

Many of these diseases typically present with lymph node enlargement, bone marrow infiltration, general and lymphoma subtype specific symptoms and laboratory abnormalities.

Novel agents have improved the prognosis of high-risk lymphoma patients in the front-line and relapsed setting and more accurate prognostic tools enable less intensive treatment for low-risk patients, while maintaining their good prognosis.

Lymphoma disease have not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardized documentation of epidemiology, clinical course and molecular and other biologic data of this disease. As lymphomas are a very heterogeneous group, not all subtypes will always be documented simultaneously in this registry. Which lymphoma subtype is to be documented can change over time, depending on which clinical question is currently in focus.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The registry will include patients ≥ 18 years with lymphoma.  Exclusion Criteria:  There are no specific exclusion criteria. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Interested sites that treat patients in this indication will be invited to participate in this registry. - SamplingMethod: Probability Sample
ED50 of Esketamine for Laser Treatment in Children
Status: Not yet recruiting

There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age between 3 years and 12 years old patients scheduled for laser treatment of facial lesion  Exclusion Criteria:  patients with airway infection during the last 1 month patients with cardiac or pulmonary disorder patients with hepatic or renal disfunction patients with neurologic or psychiatric disorder - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Years - MaximumAge: 12 Years - StdAgeList: Child
A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases
Status: Recruiting

Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 7 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.

Only one eye per subject can be enrolled.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Given written Informed Consent by subject, Other, ...  Exclusion Criteria:  Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator), Other, ... - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 85 Years - StdAgeList: Adult, Older Adult
Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)
Status: Recruiting

The primary objective of the REACT randomized clinical trial (RCT) is to optimize the clinical benefit from adjunctive clarithromycin treatment shown in the ACCESS trial and to provide evidence for the clinical benefit of early start of adjunctive oral clarithromycin guided by suPAR to prevent the progression into sepsis in patients with community-acquired pneumonia (CAP) at risk. This can be achieved by endpoints incorporating clinical benefit with the effect of treatment on the improvement of the immune dysregulation of CAP. The secondary objectives of REACT are to investigate the impact of early adjunctive treatment with clarithromycin on the resolution of CAP at the test-of-cure (TOC) visit.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age equal to or above 18 years Male or female gender In case of women of reproductive age, willingness to use dual contraceptive method during the study period Written informed consent provided by the patient. For subjects without decision-making capacity, informed consent must be obtained from a legally designated representative following the national legislation Community-acquired pneumonia (CAP) Presence of at least two of the following signs: i) cough; ii) purulent sputum expectoration; iii) dyspnea; and/or iv) pleuritic chest pain PCT ≥0.25 ng/ml suPAR ≥6 ng/ml  Exclusion Criteria:  Age below 18 years Denial of written informed consent Any stage IV malignancy Any do not resuscitate decision Patients necessitating non-invasive ventilation or mechanical ventilation Hospitalization in Intensive Care Unit Infection by SARS-CoV-2 Oral or IV intake of corticosteroids at a daily dose equal to or greater than 0.4 mg/kg prednisone for a period greater than the last 15 days Intake of any macrolide for the current episode of CAP under study Known infection by the human immunodeficiency virus Any chronic anti-cytokine treatment for more than two months QTc interval at rest in the ECG ≥500 msec or history of know long QT syndrome Medical history of allergy to macrolides Concomitant oral intake of astemizole, cizapride, doperidone, pimozide, terfenadine, midazolam, ranolazine, ergot alkaloids (e.g. ergotamine and dihydroergotamine), lomitapide and colchicine; patients may be enrolled in the trial if they stop these drugs during trial participation. Medical history of torsades de pointes arrhythmia Concomitant intake of lovostatin or simvastatin; patients may be enrolled in the trial if they stop these drugs during trial participation. Concomitant presence of end-stage liver failure and end-stage renal failure. Severe hypokalemia or severe hypomagnesemia; a patient may be enrolled one any of these electrolyte disturbances are restored. Any contradictions for macrolide uptake Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study Participation in any other interventional trial within the last 30 days - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Evaluation of Free Gingival Graft Timing
Status: Not yet recruiting

This clinical trial aims to compare and evaluate the clinical outcomes between two distinct treatment sequences: free gingival graft surgery preceding guided bone regeneration and guided bone regeneration followed by free gingival graft.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  • At least 18 years old  No uncontrolled medical conditions or medications that will affect their bone healing. Good oral hygiene is defined as a full-mouth plaque score ≤25%11. Must be able to read and understand the informed consent document. Has a need for implants to replace missing tooth/teeth in at least 1 quadrant of the mouth. Insufficient alveolar ridge width for endosseous implant placement, defined as 5 mm or less, as determined by bone sounding and CBCT scan. The patient and/or guardian is willing and able to comply with pre-operative and post-operative diagnostic and clinical evaluations required. The patient is not pregnant or breastfeeding.  Exclusion Criteria:  Active infectious diseases.  Liver or kidney dysfunction/failure. Uncontrolled diabetes (HbA1c ≥ 8.5). Active cancer treatment - such as active chemotherapy radiation therapy, or radiotherapy performed within ≤12 months from the procedure. Taking medications that will affect their bone healing (for example, bisphosphonates and long-term anti-inflammatory medications). Metabolic bone diseases that affect bone healing such as osteoporosis. Pregnant or lactating women (self-reported). Current tobacco and Marijuana smokers have 10 or more cigarettes per day, and former smokers (&gt; 10 cigarettes) who quit &lt; 10 ago (self-reported). Poor oral hygiene. Vertical loss of bone at the edentulous ridge. History of periodontal disease. The patient is pregnant or breastfeeding - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
Status: Not yet recruiting

The purpose of the study is to test how successful the retrieval rate of the new HydroMARK Plus Breast Biopsy Site Marker in comparison to HydroMARK.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with biopsy clips scheduled for surgery with SCOUT localization  Exclusion Criteria:  Patients who didn't have surgery, patients younger than 18 years old Patients older than 90 years old Inmates Non-English speakers - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult